Reactivation in B-cells is critical for the Epstein Barr virus (EBV) life cycle and it plays a role in amplifying viral titers in AIDS patients. The repertoire of EBV genes thought to be involved in viral replication consists primarily of approximately 80-90 protein-coding genes. These viral proteins play very diverse roles in virus production including roles in DNA replication, RNA transcription, molecular trafficking, virion assembly, viral egress, host shut-off etc. This is not to mention roles as viron components;both components that form the virus architecture as well as those that are involved in inducing the rapid signaling responses immediately following new infection. We hypothesize that in addition to this group of known protein coding genes, EBV encodes a previously unappreciated group of long non-coding transcripts that will ultimately be found to play an equally diverse set of functions in virus replication. Conceptually this would be important because it would change the texture and the details of how most of us visualize the reactivation process. From a practical standpoint, it would give us a new class of molecular targets that may offer the application of alternative therapeutic approaches against EBV.

Public Health Relevance

The replication phase of the Epstein Barr virus results in the production of infectious virions and the spread of the virus within the host. In AIDS patients, virl proteins produced during the replication phase as well as oncogenic latency proteins are not as well targeted by the immune system, resulting in additional pathogenic consequences including lymphomas. Here we propose a new regulatory model for how EBV facilitates progression through the viral replication phase.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI106676-01A1
Application #
8750146
Study Section
Special Emphasis Panel (ZRG1-AARR-K (02))
Program Officer
Beisel, Christopher E
Project Start
2014-02-18
Project End
2019-01-31
Budget Start
2014-02-18
Budget End
2015-01-31
Support Year
1
Fiscal Year
2014
Total Cost
$376,250
Indirect Cost
$126,250
Name
Tulane University
Department
Pathology
Type
Schools of Medicine
DUNS #
053785812
City
New Orleans
State
LA
Country
United States
Zip Code
70118
Strong, Michael J; Lin, Zhen; Flemington, Erik K (2014) Expanding the conversation on high-throughput virome sequencing standards to include consideration of microbial contamination sources. MBio 5:e01989
Strong, Michael J; Xu, Guorong; Morici, Lisa et al. (2014) Microbial contamination in next generation sequencing: implications for sequence-based analysis of clinical samples. PLoS Pathog 10:e1004437
Striker, Rob; Mehle, Andrew (2014) Inhibitors of peptidyl proline isomerases as antivirals in hepatitis C and other viruses. PLoS Pathog 10:e1004428
Martin, Elizabeth C; Krebs, Adrienne E; Burks, Hope E et al. (2014) miR-155 induced transcriptome changes in the MCF-7 breast cancer cell line leads to enhanced mitogen activated protein kinase signaling. Genes Cancer 5:353-64
Zhang, Wensheng; Edwards, Andrea; Flemington, Erik et al. (2014) Somatic mutations favorable to patient survival are predominant in ovarian carcinomas. PLoS One 9:e112561
Martin, Elizabeth C; Rhodes, Lyndsay V; Elliott, Steven et al. (2014) microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity. Mol Cancer 13:229